SCYNEXIS Completes Phase 1 Study Of SCY-770, Selective And Direct AMP-Activated Protein Kinase Activator
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in
SCYNEXIS tested a new medicine that was safe in healthy people. Now they move forward to test it in patients with kidney disease.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.